Data gathered: May 29
AI Stock Analysis - Pliant Therapeutics (PLRX)
Analysis generated February 10, 2025. Powered by Chat GPT.
Pliant Therapeutics is a biopharmaceutical company focused on discovering and developing novel therapies for fibrotic diseases. The company leverages its proprietary approach based on integrin biology to develop treatments targeting fibrosis across multiple organs. From a market perspective, their approach places them at the cutting edge of therapeutic innovation in fibrotic diseases, an area with significant unmet medical need.
Stock Alerts - Pliant Therapeutics (PLRX)
 |
Pliant Therapeutics | May 28 Price is up by 7.4% in the last 24h. |
|
Pliant Therapeutics | May 21 Employee Rating is down by 6.7% over the last month. |
|
Pliant Therapeutics | May 21 Business Outlook among employees is down by 19% over the last month. |
|
Pliant Therapeutics | May 13 Price is down by -7.5% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Pliant Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Employee Rating | 84 | Sign up | Sign up | Sign up |
| Google Trends | 6 | Sign up | Sign up | Sign up |
| Patents | 27 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 1 | Sign up | Sign up | Sign up |
| Facebook Followers | 94 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 5 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,690 | Sign up | Sign up | Sign up |
| Twitter Followers | 492 | Sign up | Sign up | Sign up |
| Twitter Mentions | 17 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 113 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 81 | Sign up | Sign up | Sign up |
| Linkedin Employees | 181 | Sign up | Sign up | Sign up |
About Pliant Therapeutics
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States.
| Price | $1.35 |
| Target Price | Sign up |
| Volume | 1,010,000 |
| Market Cap | $79M |
| Year Range | $1.23 - $15.7 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of “Hold” by AnalystsMay 21 - ETF Daily News |
 |
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International ConferenceMay 21 - Yahoo |
Pliant Therapeutics, Inc. Presents Clinical and Preclinical Data At the American Thoracic Society International ConferenceMay 21 - Finnhub |
|
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 8 - Finnhub |
|
|
Renaissance Technologies LLC Cuts Stock Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX)May 5 - ETF Daily News |
|
Pliant Therapeutics (PLRX) Expected to Announce Quarterly Earnings on MondayMay 3 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 0 | 0 | 0 | -56M | 0 | -0.920 |
| Q4 '24 | 0 | 0 | 0 | -50M | -48M | -0.820 |
| Q3 '24 | 0 | 0 | 0 | -58M | -56M | -0.950 |
| Q2 '24 | 0 | 620,000 | -620,000 | -56M | -54M | -0.920 |
| Q1 '24 | 0 | 510,000 | -510,000 | -47M | -46M | -0.780 |
Insider Transactions View All
| Ouimette Mike filed to sell 70,544 shares at $11. January 22 '25 |
| Cheung Lily filed to sell 24,550 shares at $11.2. January 22 '25 |
| Ouimette Mike filed to sell 80,774 shares at $11.2. January 22 '25 |
| Lefebvre Eric filed to sell 194,574 shares at $11.2. January 22 '25 |
| Hull Hans filed to sell 211,558 shares at $11.2. January 22 '25 |
Similar companies
Read more about Pliant Therapeutics (PLRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Pliant Therapeutics?
The Market Cap of Pliant Therapeutics is $79M.
What is the current stock price of Pliant Therapeutics?
Currently, the price of one share of Pliant Therapeutics stock is $1.35.
How can I analyze the PLRX stock price chart for investment decisions?
The PLRX stock price chart above provides a comprehensive visual representation of Pliant Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Pliant Therapeutics shares. Our platform offers an up-to-date PLRX stock price chart, along with technical data analysis and alternative data insights.
Does PLRX offer dividends to its shareholders?
As of our latest update, Pliant Therapeutics (PLRX) does not offer dividends to its shareholders. Investors interested in Pliant Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Pliant Therapeutics?
Some of the similar stocks of Pliant Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.